| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| anifrolumab nda | 0.24 | 0.9 | 2492 | 94 | 15 |
| anifrolumab | 1.12 | 1 | 7986 | 14 | 11 |
| nda | 1.17 | 0.6 | 8546 | 26 | 3 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| anifrolumab ndc | 0.77 | 0.5 | 7228 | 52 |
| anifrolumab indications | 1.28 | 0.6 | 6552 | 41 |
| anifrolumab dermatomyositis | 1.39 | 0.2 | 4931 | 89 |
| anifrolumab and glioblastoma and cancer cells | 0.34 | 0.4 | 9557 | 71 |
| anifrolumab antagonizes which target molecule | 0.77 | 0.8 | 9741 | 75 |
| anifrolumab cost | 0.43 | 0.3 | 1833 | 53 |
| anifrolumab chpl | 1 | 0.4 | 1688 | 13 |
| anifrolumab clinical trials | 1.49 | 0.8 | 6475 | 25 |
| anifrolumab cadth | 0.4 | 0.1 | 3504 | 52 |
| anifrolumab cpt code | 1.75 | 0.9 | 3639 | 95 |
| anifrolumab compendium | 1.28 | 1 | 5932 | 47 |
| anifrolumab cutaneous lupus | 1.45 | 0.2 | 5113 | 74 |
| anifrolumab nejm | 1.38 | 0.4 | 7565 | 68 |
| anifrolumab nice | 1.99 | 0.1 | 2431 | 37 |
| anifrolumab nice ta | 0.54 | 0.1 | 3892 | 50 |
| anifrolumab mechanism of action | 1.22 | 0.3 | 1707 | 45 |
| anifrolumab mechanism | 1.09 | 0.7 | 9597 | 71 |
